Business Context and Reporting Period
Company: Henry Schein, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 28, 2008
Business Overview: Henry Schein is a leading distributor of healthcare products and services to office-based practitioners, including dental, medical, and animal health clinics. Operations are conducted through two reportable segments: Healthcare Distribution and Technology. The company serves over 550,000 customers globally with operations in the U.S., Canada, and 18 other countries.
Key Financial Metrics
| Metric | Three Months Ended June 28, 2008 |
Six Months Ended June 28, 2008 |
|---|---|---|
| Net Sales | $1,644,977 | $3,170,596 |
| Gross Profit | $488,415 | $939,648 |
| Gross Margin | 29.7% | 29.6% |
| Operating Income | $113,357 | $198,584 |
| Net Income | $65,477 | $117,807 |
| Diluted EPS | $0.71 | $1.28 |
| Cash from Operations | N/A | $138,617 |
| Cash & Equivalents | $271,432 | $271,432 |
| Total Debt | $454,301 | $454,301 |
| Working Capital | $1,009,305 | $1,009,305 |
Note: All figures in thousands except per share data and percentages.
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 18.6% ($258.0 million) for the quarter and 17.6% ($473.5 million) for the six months compared to the prior year. Growth was driven by 13.6% local currency growth (4.0% internal, 9.6% acquisitions) and 5.0% foreign currency exchange impact for the quarter.
- Segment Performance:
- International: Sales surged 55.7% in the quarter, driven by acquisitions (28.8%) and currency effects (16.0%).
- Dental: Sales grew 9.7%, with strong internal growth in equipment and consumables.
- Medical: Sales declined 8.3% due to a reduction in lower-margin pharmaceutical products. Excluding these, internal growth was approximately 1.0%.
- Technology: Sales increased 29.0%, driven by the Software of Excellence acquisition and growth in electronic/financial services.
- Profitability: Operating income rose 24.8% for the quarter. Gross margins remained stable at 29.7% for the quarter, though Healthcare Distribution margins dipped slightly to 28.5% due to product mix changes and the W. & J. Dunlop acquisition.
- Discontinued Operations: The prior year period included a $32.7 million loss from discontinued operations (including asset write-downs), which did not occur in the current period, contributing to the year-over-year net income improvement.
Guidance, Outlook, and Risks
- Liquidity and Capital Resources: The company maintains strong liquidity with $271.4 million in cash and equivalents and $108.9 million remaining under its stock repurchase program. Management expects to invest $27.0 million to $32.0 million in capital projects for the remainder of the fiscal year.
- Auction-Rate Securities (ARS) Risk: The company holds approximately $35.8 million in ARS ($23.9 million in student loans, $11.9 million in municipal bond funds). Since February 2008, auctions have failed to settle, creating a liquidity constraint. While the company believes these investments are not impaired and will not impact operations, it has reclassified the student loan portion to long-term assets due to the lack of market activity.
- Convertible Debt: The company has $240 million in convertible notes due in 2034. Management has sufficient funds to satisfy the cash portion of any conversion obligation.
- Accounting Changes: The company is evaluating the impact of new FASB standards (FAS 141, FAS 160, and FSP APB 14-a) regarding business combinations, noncontrolling interests, and convertible debt, which may require retrospective adjustments in future periods.
- Forward-Looking Statements: Results are subject to risks including healthcare industry consolidation, regulatory changes, foreign currency fluctuations, and dependence on third-party suppliers.
Investor Verification Checklist
- ARS Liquidity: Verify the status of the $35.8 million auction-rate securities portfolio and any potential impairment charges if auctions continue to fail.
- Medical Segment Mix: Confirm the strategic rationale and long-term impact of reducing lower-margin pharmaceutical sales in the Medical segment.
- Acquisition Integration: Assess the performance of recent acquisitions (e.g., W. & J. Dunlop, Software of Excellence) driving the majority of international and technology growth.
- Convertible Debt Impact: Monitor the implementation of FSP APB 14-a, which may result in a $32.6 million debt discount and increased interest expense in future periods.
- Working Capital Trends: Review accounts receivable days sales outstanding (41.1 days) and inventory turnover (6.5 turns) for signs of collection or inventory management issues.